These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33955591)

  • 41. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
    Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
    Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study.
    Lemoli RM; Martinelli G; Olivieri A; Motta MR; Rizzi S; Terragna C; Leopardi G; Benni M; Ronconi S; Cantori I; Rondelli D; Mangianti S; Leoni P; Montanari M; Cavo M; Tura S
    Br J Haematol; 1999 Nov; 107(2):419-28. PubMed ID: 10583236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34
    Salzmann-Manrique E; Bremm M; Huenecke S; Stech M; Orth A; Eyrich M; Schulz A; Esser R; Klingebiel T; Bader P; Herrmann E; Koehl U
    Front Immunol; 2018; 9():1841. PubMed ID: 30154788
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of transplanted cells with CD184 and CD26 expressions and reconstitution of CD3+ lymphocyte population on long-term survival after autologous hematopoietic stem cell transplantation for multiple myeloma.
    Kopinska A; Krawczyk-Kulis M; Wieczorkiewicz-Kabut A; Koclega A; Jagoda K; Dziaczkowska-Suszek J; Helbig G
    Exp Hematol; 2023 Nov; 127():52-58.e1. PubMed ID: 37666354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD133+ cell content does not influence recovery time after hematopoietic stem cell transplantation.
    Jaime-Pérez JC; Guillermo-Villanueva VA; Méndez-Ramírez N; Chapa-Rodríguez A; Gutiérrez-Aguirre H; Gómez-Almaguer D
    Transfusion; 2009 Nov; 49(11):2390-4. PubMed ID: 19903294
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma.
    Park Y; Kim DS; Jeon MJ; Lee BH; Yu ES; Kang KW; Lee SR; Sung HJ; Nam MH; Yoon SY; Choi CW; Kang ES; Cho D; Kim K; Kim BS; Kim DW; Kim SJ
    J Clin Apher; 2019 Oct; 34(5):579-588. PubMed ID: 31283042
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
    Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
    Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blood graft composition after plerixafor injection in patients with NHL.
    Varmavuo V; Mäntymaa P; Nousiainen T; Valonen P; Kuittinen T; Jantunen E
    Eur J Haematol; 2012 Aug; 89(2):128-35. PubMed ID: 22536949
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autologous peripheral blood progenitor cell transplantation with <2 x 10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment.
    Villalón L; Odriozola J; Laraña JG; Zamora C; Pérez de Oteyza J; Jodra MH; López J; Herrera P; Roldán E; Ramos ML; Ramos P; Navarro JL
    Hematol J; 2000; 1(6):374-81. PubMed ID: 11920217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen.
    Morris CL; Siegel E; Barlogie B; Cottler-Fox M; Lin P; Fassas A; Zangari M; Anaissie E; Tricot G
    Br J Haematol; 2003 Feb; 120(3):413-23. PubMed ID: 12580955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies.
    Sheppard D; Bredeson C; Allan D; Tay J
    Biol Blood Marrow Transplant; 2012 Aug; 18(8):1191-203. PubMed ID: 22261379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Multiple myeloma and autologous haematopoietic stem-cell transplantation without cryopreservation: experiences of the Clinical Hematology Department of Casablanca, Morocco].
    Fares S; Hadri H; Rachid M; Moutiqui T; Oukkache B; Quessar A
    Pan Afr Med J; 2021; 39():105. PubMed ID: 34512841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of the CD34+ 38- cells in posttransplant hematopoietic recovery.
    Hénon P; Sovalat H; Bourderont D; Ojeda-Uribe M; Arkam Y; Wunder E; Raidot JP; Husseini F; Audhuy B
    Stem Cells; 1998; 16 Suppl 1():113-22. PubMed ID: 11012153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products.
    Hermouet S; Niaussat AE; Briec A; Pineau D; Robillard N; Bataille R; Milpied N; Harousseau JL; Mahé B
    Hematol Cell Ther; 1997 Dec; 39(6):317-25. PubMed ID: 9497891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only.
    LeBlanc R; Claveau JS; Ahmad I; Delisle JS; Bambace N; Bernard L; Cohen S; Kiss T; Lachance S; Landais S; Roy DC; Sauvageau G; Roy J
    Clin Transplant; 2020 Dec; 34(12):e14099. PubMed ID: 32981146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.